Danish biotechnology company Genmab has entered into an additional antibody-drug conjugate (ADC) collaboration with US-based Seattle Genetics.
As part of the new agreement, Genmab will pay an upfront fee of $11m for exclusive rights to use Seattle Genetics’ auristatin-based ADC technology with firm’s HuMax-AXL, an antibody targeting AXL that is expressed on multiple types of solid cancers.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In September 2010, both companies partnered for HuMax-TF-ADC, targeting the Tissue Factor antigen. It is in Phase I trial for solid tumours.
In addition, Seattle Genetics has been entitled to receive around $200m in potential milestone payments and mid-to-high single digit royalties on worldwide net sales of any resulting products.
The company can exercise an option to increase the royalties to double digits in exchange for a reduction of the milestone payments owed by Genmab, before its initiation of a Phase III study for any resulting products.
Seattle Genetics corporate development vice-president Natasha Hernday said: "This collaboration with Genmab further extends the reach of our industry-leading ADC technology for use with novel oncology targets, while providing us with a compelling financial value proposition as the programme advances.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataGenmab CEO Jan van de Winkel said: "This new collaboration with Seattle Genetics adds another ADC programme to our innovative pre-clinical pipeline of antibodies developed using the latest technological advances in cancer therapeutics. Pre-clinical work identified AXL as an excellent target for an ADC therapeutic approach."
HuMax-AXL-ADC is an antibody-drug conjugate (ADC), which combines high affinity human monoclonal antibody against AXL with Seattle Genetics’ clinically validated cytotoxic drug.
AXL is a signalling molecule that involves in multiple processes of tumour development and progression, while ADCs are monoclonal antibodies, which are developed to deliver cytotoxic agents to tumour cells.
